Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study
Long-term follow-up confirms durable responses with cemiplimab in patients with advanced cutaneous squamous cell carcinoma in Australia treated on the EMPOWER-CSCC-1 trial.
Authors
- Alexander Guminski (ORCID: https://orcid.org/0000-0003-3681-7015)
- Annette M. Lim (ORCID: https://orcid.org/0000-0002-0777-2279)
- Luke McLean (ORCID: https://orcid.org/0000-0002-5969-1577)
- Mathias Bressel (ORCID: https://orcid.org/0000-0002-9718-9596)
- Catherine Bennett
- Brett Hughes (ORCID: https://orcid.org/0000-0002-1811-0537)
- Danny Rischin (ORCID: https://orcid.org/0000-0002-3368-0386)
- Samantha Bowyer (ORCID: https://orcid.org/0000-0002-3357-2836)
- Brian Stein
Institutions
- Royal Brisbane and Women's Hospital (AU)
- Royal North Shore Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Sir Charles Gairdner Hospital (AU)
- Centre for Cancer Biology (AU)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1016/j.jaad.2025.11.080
- Citations
- 1
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35